Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Equity Average (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Equity Average for 15 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 66.08% year-over-year to $3.5 million, compared with a TTM value of $3.5 million through Sep 2025, down 66.08%, and an annual FY2024 reading of $9.3 million, down 8.67% over the prior year.
  • Equity Average was $3.5 million for Q3 2025 at BioRestorative Therapies, down from $5.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $12.7 million in Q2 2024 and bottomed at -$4.3 million in Q3 2021.
  • Average Equity Average over 5 years is $6.5 million, with a median of $8.4 million recorded in 2022.
  • The sharpest move saw Equity Average skyrocketed 515.66% in 2022, then plummeted 66.08% in 2025.
  • Year by year, Equity Average stood at $3.0 million in 2021, then surged by 240.04% to $10.0 million in 2022, then increased by 3.44% to $10.4 million in 2023, then fell by 10.8% to $9.3 million in 2024, then crashed by 61.93% to $3.5 million in 2025.
  • Business Quant data shows Equity Average for BRTX at $3.5 million in Q3 2025, $5.5 million in Q2 2025, and $7.3 million in Q1 2025.